In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity ...

Recent years have witnessed a wave of FDA approvals and regulatory greenlights for novel antisense oligonucleotide therapies, significantly boosting confidence in their clinical potential. For ...

Long-term outcome of 117 patients with Erdheim-Chester disease and mixed histiocytosis receiving targeted therapies (BRAF and MEK inhibitors): A monocentric experience. A phase I clinical trial ...

The drug belongs to an emerging and highly promising class that uses short pieces of DNA, called antisense oligonucleotides, or ASOs, to silence specific genes and halt the production of the ...

Last, certainly not least, is AMX one fourteen, which shows our antisense oligonucleotide targeting calpane two, which is a well known target in neurodegenerative disease. But this is the first ...

Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...

(B) Mechanism of action of toxin-conjugates delivered via CED. Toxin conjugate binds appropriate tumor cell surface receptor via ligand component of conjugate. Following endocytosis of the conjugate, ...

The company anticipates submitting an Investigational New Drug application in early 2026. Phase 1 human trials are expected to begin shortly thereafter. In vitro, HT-KIT reduced KIT expression by more ...

How can this report add value to an organization? Product/Innovation Strategy: This report provides a comprehensive product/innovation strategy for the antibody conjugate oligonucleotide market, ...